Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E24.39 EPS (ttm)1.42 Insider Own0.02% Shs Outstand6.30B Perf Week-0.06%
Market Cap218.25B Forward P/E15.56 EPS next Y2.23 Insider Trans-20.42% Shs Float6.30B Perf Month10.42%
Income9.09B PEG11.26 EPS next Q0.49 Inst Own72.00% Short Float3.29% Perf Quarter11.78%
Sales49.61B P/S4.40 EPS this Y-14.50% Inst Trans0.01% Short Ratio7.31 Perf Half Y20.45%
Book/sh12.38 P/B2.80 EPS next Y7.38% ROA6.70% Target Price35.83 Perf Year9.76%
Cash/sh5.31 P/C6.53 EPS next 5Y2.17% ROE14.90% 52W Range27.03 - 34.97 Perf YTD12.18%
Dividend1.12 P/FCF- EPS past 5Y3.10% ROI8.70% 52W High-0.94% Beta0.75
Dividend %3.23% Quick Ratio2.50 Sales past 5Y0.10% Gross Margin80.80% 52W Low28.14% ATR0.59
Employees77700 Current Ratio2.90 Sales Q/Q-3.20% Oper. Margin29.50% RSI (14)64.30 Volatility1.42% 1.58%
OptionableYes Debt/Eq0.48 EPS Q/Q-50.00% Profit Margin23.10% Rel Volume0.68 Prev Close34.64
ShortableYes LT Debt/Eq0.41 EarningsJan 27 BMO Payout43.10% Avg Volume28.37M Price34.64
Recom2.20 SMA201.36% SMA505.84% SMA20015.15% Volume0 Change0.00%
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Aug-05-11Upgrade Standpoint Research Hold → Buy $21
Mar-14-11Downgrade Standpoint Research Buy → Hold
Nov-03-10Downgrade Argus Buy → Hold
May-21-10Initiated Jefferies Buy $17.80
Dec-16-09Initiated UBS Buy
Apr-27-09Initiated Standpoint Research Buy $20
Feb-12-09Upgrade Leerink Swann Mkt Perform → Outperform
Mar-04-15 07:05PM  Parsing the SalixValeant merger MAC clause: Part 2 Market Realist
07:05PM  Parsing the SalixValeant merger MAC clause: Part 1 Market Realist
06:20PM  Your first trade for Thursday at CNBC
05:58PM  Fast Money Final Trade: FL, QQQ, IRET & PFE CNBC
11:02AM  These 10 stocks could be due for a shake-up this year at CNBC
Mar-03-15 05:37PM  Following the big bucks to the exit CNBC
12:06PM  Prevnar, Pfizer's pneumonia vaccine, okayed for adults in EU AP
08:35AM  Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults Business Wire
08:23AM  If You 'Want To Make A Good Drug Great' Cost Must Be Factored In at Forbes
04:10AM  Why we're cautious about 2015: Germany's Merck at CNBC
Mar-02-15 06:47PM  How A Strong Greenback Dollar Affects the Economy at Investopedia
06:05PM  Elliott Management starts new position in Cubist Pharmaceuticals Market Realist
12:37PM  Mallinckrodt PLC (MNK), Pfizer Inc. (PFE): Healthcor Managements Top 5 Health Stocks at Insider Monkey
10:46AM  How To Trade The Biggest Gainers Among The Dow 30 at Forbes
09:30AM  The Zacks Analyst Blog Highlights: Boeing, Home Depot, Chevron, Pfizer and 3M - Press Releases Zacks
Feb-27-15 05:02PM  PFIZER INC Files SEC form 10-K, Annual Report EDGAR Online
04:15PM  Interested In Pharmaceutical Stocks? Try Novartis (ADR) at Investopedia
04:14PM  Dow 30 Stock Roundup: Home Depot Beats, Chevron Issues $6B in Bonds - Analyst Blog Zacks
03:05PM  The SalixValeant merger: Basics of Salix Pharmaceuticals Market Realist
03:05PM  Increased Mergers and Acquistions Help, But Headwinds Persist Market Realist
12:24PM  Kahn Brothers Top Picks to Close 2014, as Founder Irving Kahn Passes at 109 at Insider Monkey
11:06AM  Rationale of the SalixValeant merger Market Realist
10:46AM  Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Company Spotlight
08:04AM  Why should you invest in healthcare ETFs? Market Realist
Feb-26-15 05:27PM  Stock Goes Nuts As Akorn Cracks Q4 EPS, '15 Views Investor's Business Daily
05:06PM  Basics of the SalixValeant merger transaction Market Realist
02:50PM  Pfizer, Novartis say meningitis vaccine scope too narrow Reuters
01:11PM  Apple Inc. (AAPL) is 14% Overvalued, S&P 500 16%: Canadian Fund Manager at Insider Monkey
01:02PM  The SalixValeant merger will follow a cash tender timeline Market Realist
12:29PM  CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk Business Wire
12:31AM  [$$] Sanofi Wins Approval For New Insulin Drug, An Early Test For New CEO at The Wall Street Journal
Feb-25-15 07:56PM  The hot health care stocks to buy now for your 401(K) Fox Business Video
07:04AM  Stocks on fire in February CNBC
06:04AM  Fresenius Medical Care sees strong profit growth in 2016 Reuters
12:34AM  [$$] Pfizer Australia Lipitor Case Dismissed at The Wall Street Journal
Feb-24-15 06:05PM  Key points of the Baker Hughes and Halliburton merger Market Realist
11:45AM  Volatility Index signals that the bull has room to run at MarketWatch
10:00AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
09:04AM  Pfizer Meningitis B Vaccine Shows Positive Results at The Wall Street Journal
08:00AM  Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA┬« (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis (Tdap) Vaccines In Adolescents Business Wire
Feb-23-15 06:26PM  Agilent-ONO Companion Diagnostics Aim - Analyst Blog Zacks
04:27PM  Pfizer Rapamune Under FDA Priority Review for Lung Disease - Analyst Blog Zacks
08:23AM  Billionaire John Paulson Backs Valeant's Takeover Of Salix Pharmaceuticals Amid Consolidation Bet at Forbes
Feb-22-15 09:17AM  High Value But Little Glory: Innovating The Unmentionable at Forbes
Feb-20-15 02:40PM  Eli Lilly Extends Phase III Cholesterol Study by Six Months - Analyst Blog Zacks
01:09PM  A 'Great Entry Point' for AbbVie; Pfizer a 'Value Creation Machine' at Barrons.com
12:28PM  What it takes to be called big pharma Market Realist
10:30AM  FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE┬« (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM) Business Wire
09:34AM  Dow 30 Stock Roundup: Wal-Mart Beats on Earnings, Coke Hikes Dividend - Analyst Blog Zacks
07:02AM  Trouble in index city at USA TODAY
Feb-19-15 06:30PM  Sanofi Hires Brandicourt, a Bayer and Pfizer Veteran, as CEO at The Wall Street Journal
05:32PM  Hot Dividend Stocks: Pfizer Pulls Back Into Buy Range at Investor's Business Daily
04:56PM  Sanofi's new CEO CNBC
02:54PM  10 Most Popular Healthcare Stocks Among Hedge Funds at Insider Monkey
Feb-18-15 05:05PM  Parsing the Office Depot Material Adverse Change clause, part 1 Market Realist
09:06AM  Basics of Office Depot Market Realist
08:18AM  John Oliver's Big Pharma Rant Is Amusing -- But Misleading at Forbes
Feb-17-15 05:17PM  Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog Zacks
04:59PM  CVS girds for battle over cholesterol drugs at MarketWatch
04:32PM  Pfizer NDA on Pain Management Candidate Accepted by FDA - Analyst Blog Zacks
11:07AM  Understand the basics of the StaplesOffice Depot merger Market Realist
10:20AM  Gainers and losers in Mass. tech last week: CyberArk shares soar 47% at American City Business Journals
08:30AM  Global Pharma's R&D Re-Balancing at Forbes
Feb-16-15 01:05PM  The punch line: Should you set up the HospiraPfizer deal? Market Realist
10:06AM  The HospiraPfizer merger: Assessing your risks and rewards Market Realist
08:36AM  If Pfizer's Right, Hospira Biosimilar Gold Rush Begins at Forbes
Feb-13-15 02:42PM  Dow 30 Stock Roundup: Cisco, Coke Beat, Microsoft Issues $10.8B in Bonds - Analyst Blog Zacks
01:06PM  Parsing the Hospira material adverse change clause, Part II Market Realist
12:16PM  Deal stocks rise, emboldening bankers, bull run at CNBC
10:27AM  Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Business Wire
Feb-12-15 05:06PM  Parsing the Hospira material adverse change clause, Part I Market Realist
04:00PM  For many of China's biotech brains-in-exile, it's time to come home Reuters
01:06PM  Pfizer: Quintessentially big pharma Market Realist
10:28AM  Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog Zacks
07:00AM  Pfizer Inc. (PFE): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Feb-11-15 06:26PM  Your first trade for Thursday at CNBC
05:58PM  Fast Money Final Trade: PFE, LMT, KO & GT CNBC
03:06PM  HospiraPfizer merger: Benefits from growing biosimilars market Market Realist
12:30PM  Pfenex Up on Lucentis Biosimilar Collaboration with Hospira - Analyst Blog Zacks
11:16AM  Coming To An App Store Near You: Drug-Like Interventions at Forbes
11:06AM  Getting the HospiraPfizer merger deal done Market Realist
Feb-10-15 06:20PM  Your first trade for Wednesday, February 11 at CNBC
05:58PM  Fast Money Final Trade: Stay in GM CNBC
02:43PM  Pfizer Starts Accelerated $5B Share Repurchase Program - Analyst Blog Zacks
12:59PM  Canadian government to require drug shortage notice Reuters
11:19AM  Why Pfizer is Worth $40 at Barrons.com
10:40AM  Will Hospira (HSP) Miss Q4 Earnings on Low Precedex Sales? - Analyst Blog Zacks
10:36AM  Stocks Open Up In Rising Trade; Qualys And Taiwan Semi Soar at Investor's Business Daily
09:00AM  PFIZER INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Feb-09-15 07:14PM  Pfizer to repurchase $5 billion in stock in accelerated plan AP
06:00PM  Pfizer in $5 billion accelerated buyback deal with Goldman, Sachs & Co Reuters
05:58PM  Pfizer in $5 bln accelerated buyback deal with Goldman, Sachs & Co Reuters
05:27PM  Pfizer Commences $5 Billion Accelerated Share Repurchase Business Wire
02:31PM  Pfizer's Hospira Acquisition Good for Its Stock But What About Its Bonds? at Barrons.com
02:30PM  Will Zoetis (ZTS) Earnings Disappoint Expectation in Q4? - Analyst Blog Zacks
02:20PM  McDonalds deserves a break today at Fortune
10:10AM  Stock Market News for February 30, 2015 - Market News Zacks
10:00AM  Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Investor Conference Business Wire
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Hospira, Impax Laboratories and OphthotechThe Zacks Analyst Blog Highlights: Pfizer, Hospira, Impax Laboratories and Ophthotech - Press Releases Zacks
09:30AM  The Zacks Analyst Blog Highlights: BP, Walt Disney, Pfizer, Hospira and ExxonMobil - Press Releases Zacks
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company's Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company's Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd.; and strategic collaboration with iTeos Therapeutics SA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM
HILL CHARLES HExecutive Vice PresidentNov 10Sale30.188,285250,04199,478Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Option Exercise26.2021,600565,920123,462Nov 10 05:34 PM
DAMELIO FRANK AExecutive Vice PresidentNov 07Sale29.7807454,687Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Sale29.8921,600645,548101,862Nov 10 05:34 PM
READ IAN CChairman & CEOOct 30Option Exercise17.0354,585929,5831,465,906Nov 03 06:23 PM
DAMELIO FRANK AExecutive Vice PresidentOct 30Option Exercise17.0365,5021,115,499501,494Nov 03 06:23 PM
READ IAN CChairman & CEOOct 30Sale29.7667,5002,008,8001,358,862Nov 03 06:23 PM
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Option Exercise26.2036,275950,40593,010Jun 13 12:29 PM
OLSON LAURIE JExecutive Vice PresidentJun 12Sale29.5336,2751,071,27856,735Jun 13 12:29 PM
YOUNG JOHN DGroup PresidentMar 17Sale31.389,000282,42099,647Mar 18 09:33 AM
PFIZER INC10% OwnerMar 12Buy11.00272,7272,999,9971,235,330Mar 14 03:27 PM